Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Genomics USA
AddedFeb 15, 2024
UpdatedJun 18, 2026
Genomics USA

Genomics USA

Closed

Genomics USA, Inc.: Innovating microarray technologies for HLA typing, personalized treatments, and vaccine development.

HQ
Tucson, AZ, US
Founded
2004
Overview
Compare
Fundraising
Employees
Website

Genomics USA, Inc. was founded with the mission to innovate in the field of genetics and personalized medicine through advanced microarray technologies. The company focuses on Human Leukocyte Antigen (HLA) typing directly from raw biological samples, bypassing traditional DNA purification methods. Their core products include HLA Chip technology for applications in tissue transplantation, stem cell therapeutics, vaccine development, and personalized treatments for autoimmune diseases. Genomics USA aims to revolutionize healthcare by providing precise and efficient genetic analysis tools.

Notable figures associated with Genomics USA include a diverse team of experts and a scientific advisory board that guides their technological advancements. The company has successfully penetrated the growing market of genetics and personalized medicine, marked by the development of their unique microarray technology. Their key achievements include the creation of HLA typing solutions that enhance the accuracy and speed of genetic testing, thereby significantly impacting fields such as transplant compatibility and personalized healthcare.

Genomics USA - Quick Facts

When was Genomics USA founded?

Genomics USA was founded in 2004.

Where is Genomics USA's headquarters located?

Genomics USA's headquarters is located in Tucson, AZ, US.

When was Genomics USA's last funding round?

Genomics USA's most recent funding round was for $837.4k (USD) in June 2013.

How much has Genomics USA raised to-date?

As of Jun 11, 2013, Genomics USA has raised a total of $837.4k (USD).

Genomics USA - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • HLA Typing
  • Microarrays
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
ISIC
  • 7210Research and experimental development on natural sciences and engineering
Show 16 more industry codes
NAICS
  • 513200Software Publishers
  • 541500Computer Systems Design and Related Services
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC
  • 7300Business Services
  • 8000Health Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7371Computer Programming Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified